In this issue of Heart Failure Clinics, guest editors Drs. Giuseppe Limongelli, Michele Emdin, Marco Merlo, and Claudio Rapezzi bring their considerable expertise to the topic of Amyloid Cardiomyopathies:: Clinical, Diagnostic and Therapeutic Aspects. Top experts in the field discuss the role of clinical use of biomarkers in cardiac amyloidosis; cardiac magnetic resonance in the management of cardiac amyloidosis; bone scintigraphy:: strength points and pitfalls in the diagnosis of ATTR-cardiac amyloidosis; PET and cardiac amyloidosis; endomyocardial biopsy in the diagnosis of cardiac amyloidosis; and much more.
Amyloidosis and Amyloidogenesis: One Name, Many Diseases Pathophysiology of Cardiac Amyloidosis The Role of Echocardiography for the Clinical Diagnosis, Risk Stratification, and Management of Cardiac Amyloidosis Clinical Use of Biomarkers in Cardiac Amyloidosis Cardiovascular Magnetic Resonance in the Management of Cardiac Amyloidosis: Current and Future Clinical Applications The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update Standard Therapy in Cardiac Amyloidosis: What is Known, What is “Gray” Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis
Komentarze (0)
Chwilowo nie możesz polubić tej opinii
Zgłoś komentarz
Czy jesteś pewien, że chcesz zgłosić ten komentarz?
Zgłoszenie wysłane
Twój komentarz został wysłany i będzie widoczny po zatwierdzeniu przez moderatora.